KM Research Hub
← 返回论文库
待处理 入排:符合 图源:待检查 入排置信度 1.00

Pembrolizumab in Asian patients with microsatellite-instability-high/mismatch-repair-deficient colorectal cancer.

Takayuki Yoshino, Thierry Andre, Tae Won Kim, Wei Peng Yong, Kai-Keen Shiu, Benny Vittrup Jensen, Lars Henrik Jensen, Cornelis J A Punt, Denis Smith, Rocio Garcia-Carbonero, Julia Alcaide-Garcia, Peter Gibbs, Christelle de la Fouchardiere, Fernando Rivera, Elena Elez, Dung T Le, Noriaki Adachi, David Fogelman, Patricia Marinello, Luis A Diaz

Cancer Sci 114(3) 1026-1036

PMID36369901
PMCIDPMC9986093
DOI10.1111/cas.15650
发表日期2022-11-12
入排依据:命中用户提供的消化道肿瘤阳性参考集。
摘要

摘要

The phase 3 KEYNOTE-177 study evaluated pembrolizumab versus chemotherapy with or without bevacizumab or cetuximab in patients with newly diagnosed, microsatellite-instability-high (MSI-H)/mismatch-repair-deficient (dMMR) metastatic colorectal cancer (mCRC). Primary endpoints were progression-free survival (PFS) per RECIST v1.1 by blinded independent central review (BICR) and overall survival (OS). Secondary endpoints were overall response rate (ORR) per RECIST v1.1 by BICR and safety. Here, we report results from the post hoc analysis of patients who were enrolled in Asia from the final analysis (FA) of KEYNOTE-177. A total of 48 patients from Japan, Korea, Singapore, and Taiwan (pembrolizumab, n = 22; chemotherapy, n = 26) were included. At FA, median time from randomization to data cutoff (February 19, 2021) was 45.3 (range 38.1-57.8) months with pembrolizumab and 43.9 (range 36.6-55.1) months with chemotherapy. Median PFS was not reached (NR; 95% confidence interval [CI] 1.9 months-NR) with pembrolizumab versus 10.4 (95% CI 6.3-22.0) months with chemotherapy (hazard ratio [HR] 0.56, 95% CI 0.26-1.20). Median OS was NR (range 13.8 months-NR) versus 30.0 (14.7-NR) months (HR 0.65, 95% CI 0.27-1.55) and ORR was 50% (95% CI 28-72) versus 46% (95% CI 27-67). Grade 3/4 treatment-related adverse events (TRAEs) were reported by two patients (9%) in the pembrolizumab arm and 20 (80%) in the chemotherapy arm. Immune-mediated adverse events or infusion reactions were reported by six patients (27%) and 10 patients (40%), respectively. No deaths due to TRAEs occurred. These data support first-line pembrolizumab as a standard of care for patients from Asia with MSI-H/dMMR mCRC. ClinicalTrials.gov identifier: NCT02563002.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。